Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2005.216 | A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-week Study Evaluating the Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20mg and 40mg Alone or in Combination with 12.5 mg to 25 mg of Hydrochlorothiazide in Subjects with Mild to Moderate Essential Hypertension | Prof. Lee Albert |
| 2009.274 | A Phase III, multi-center, placebo-controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens | Prof. Mok Tony S. K. |
| 2026.180 | A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas | Prof. CHAN Stephen Lam |
| 2006.303 | A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474 (ZACTIMA | Prof. Mok S.K. Tony |
| 2003.399 | A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicountry and Multi-Center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals | Prof. Nelson E.A.S. |
| 2019.476 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2014.095 | A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. | Dr. WONG Lawrence Ka Sing |
| 2014.111 | A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. | Dr. WONG Raymond Siu Ming |
| 2014.520 | A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease | Prof. WONG Carmen |
| 2014.417 | A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease | Prof. HUI David Shu Cheong |
| 2004.438 | A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease | Prof. Yu Cheuk Man |
| 2022.288 | A Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer | Dr. CHAN Jason Ying Kuen |
| 2011.603 | A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER | Dr. POON Darren Ming Chun |
| 2016.262 | A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2011.257 | A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy | Dr. HUI Edwin Pun |
| 2011.278 | A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy | Dr. WONG Raymond Siu Ming |
| 2009.141 | A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy with Metformin and Pioglitazone | Dr. Lau Wing Yan |
| 2009.159 | A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Combination Therapy with Metformin and Pioglitazone | Prof. Tomlinson Brian |
| 2006.251 | A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy with Metformin and A PPARy Agonist | Prof. Tong Chun Yip Peter |
| 2007.383 | A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium | Prof. LEUNG Ping Chung |
| 2009.444 | A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2021.548 | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer (VOLGA) |
Dr. TEOH Jeremy Yuen Chun 張源津 |
| 2003.372 | A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma | Prof. Chan Anthony |
| 2015.582 | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2014.201 | A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™ | Dr Cheung Tak Hong |
| 2009.586 | A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus | Dr. Cheung Tak Hong |
| 2019.416 | A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) | Dr. CHAN Stephen Lam |
| 2021.037 | A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS |
Prof. HUI Shu Cheong David 許樹昌教授 |
| 2009.398 | A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation | Prof. Lai Paul B.S. |
| 2014.584 | A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer | Prof. YEO Winnie |
| 2004.421 | A Phase III Randomized, Double-Blind Study to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Adriamycin-Cyclophosphamide Adjuvant Chemotherapy in Chinese Breast Cancer Patients | Prof. Yeo Winnie |
| 2019.407 | A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS 181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects | Dr. LI Timothy Chun Man |
| 2011.522 | A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Monotherapy | Dr. OZAKI Risa |
| 2011.520 | A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Monotherapy | Dr. Kung Kenny |
| 2012.059 | A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Monotherapy | Dr. Tsang Chiu-Chi |
| 2010.344 | A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension period in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatment | Dr. OZAKI Risa |
| 2011.602 | A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM. IMPRESS- (IRESSATM Mutation Positive Multicentre Treatment Beyond ProgRESsion Study) | Prof. MOK Tony |
| 2012.145 | A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study] | Prof. YEO Winnie |
| 2009.545 | A Phase III Placebo-controlled Trial of Celecoxib in Genotype Positive Subjects with Familial Adenomatous Polyposis | Prof. Ng Simon Siu Man |
| 2016.290 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma |
Prof. YEO Winnie 楊明明 |
| 2021.032 | A PHASE III OPEN LABEL EXTENSION STUDY TO EVALUATE LONG TERM SAFETY AND EFFICACY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2006.008 | A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis (NKT102552) | Prof. Gin Tony |
| 2020.556 | A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS | Dr. CHOI Joseph Chun Ho |
| 2011.151 | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended- Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia | Prof. Tomlinson Brian |
| 2011.103 | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended- Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia | Dr So Wing Yee |
| 2011.110 | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended- Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia | Prof. Lam Yat Yin |
| 2004.098 | A Phase III Multi-National, Multi-Centre, Open Label, 52 week Safety Study to Assess the Safety of Re-Exposure after a Variable Interval and Subsequent Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (dosed at weeks 0, 2 and 4 then 4-weekly to Week 48), in the Treatment of Patients with Active Crohn's Disease who have previously been withdrawn from Studies CDP870-031 or CDP870-032 due to an exacerbation of Crohn's disease | Prof. Leung Wai Keung |
| 2004.097 | A Phase III Multi-National, Multi-Centre, Open Label, 52 week Safety Study to Assess the Safety of Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (dosed 4-weekly to Week 48), in the Treatment of Patients with Active Crohn | Prof. Leung Wai Keung |
| 2004.096 | A Phase III Multi-National, Multi-Centre, Double-Blind Placebo-Controlled Parallel Group, 26 week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (dosed at Weeks 0,2,4 then 4-weekly to Week 24), in the Treatment of Patients with Active Crohn | Prof. Leung Wai Keung |
| 2024.342 | A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY-Gastric 01) | Prof. YEO Winnie |
Page 263 of 288.